Search
Drozitumab
go.drugbank.com/drugs/DB19106InvestigationalIt was developed by Genentech as a drug for the treatment of cancers
Aftobetin
go.drugbank.com/drugs/DB20425InvestigationalAftobetin is under investigation in clinical trial NCT02928211 (Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations).
Irampanel
go.drugbank.com/drugs/DB21123InvestigationalIrampanel is under investigation in clinical trial NCT02222961 (Single Increasing Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Male Volunteers).
Rimexolone
go.drugbank.com/drugs/DB00896ApprovedWithdrawnRimexolone is a 1% eye drop solution is a glucocorticoid steroid. It is used to treat inflammation in the eye. It is marketed as Vexol.
Dexmedetomidine
go.drugbank.com/drugs/DB00633ApprovedInvestigationalVet approvedAn agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine.
Carteolol
go.drugbank.com/drugs/DB00521ApprovedA beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.
Doxacurium
go.drugbank.com/drugs/DB01135ApprovedWithdrawnDoxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration.
Zoledronic acid
go.drugbank.com/drugs/DB00399ApprovedInvestigationalZoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hype...
Fenofibric acid
go.drugbank.com/drugs/DB13873ApprovedInvestigationalFenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, a...
IDM-2
go.drugbank.com/drugs/DB05293ExperimentalIDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.